This executive summary from the Investment Banking Division of DNB//Back Bay focuses on a macro environment overview of current US economic markets, policy and regulatory updates in light of the current administration’s full-spectrum overhaul of US healthcare policies and the life science ecosystems and healthcare market activity as it relates to healthcare dealmaking in the US and Europe.
Read MoreAs 2024 drew to a close, a surge of Chinese dealmaking led many industry watchers to wonder if a transformative shift in the biotech industry has begun—one that could profoundly impact the future of early-stage drug development.
Read More